A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
NCT02702141
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin Lymphoma
DLBCL
Diffuse Large B-cell Lymphoma
Grade 3 Follicular Lymphoma
Interventions
DRUG:
SGN-CD19B
Sponsor
Seagen Inc.